Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jul 21:7:350.
doi: 10.3389/fmed.2020.00350. eCollection 2020.

Anticoagulation Therapy for Non-valvular Atrial Fibrillation: A Mini-Review

Jia Wu  1 , Yonggang Zhang  2 , Xiaoyang Liao  1 , Yi Lei  1
Affiliations
Review

Anticoagulation Therapy for Non-valvular Atrial Fibrillation: A Mini-Review

Jia Wu et al. Front Med (Lausanne). .

Abstract

Anticoagulation therapy is an important method of preventing stroke in individuals with atrial fibrillation (AF). Atrial fibrillation is a quivering or irregular heartbeat that can lead to blood clots, stroke, heart failure, and other heart-related complications. Clinical guidelines on AF consistently recommend long-term oral warfarin to treat valvular atrial fibrillation (VAF). However, due to varying risks of blood clots and stroke associated with different types of non-valvular atrial fibrillation NVAF, it is unclear whether direct oral anticoagulant (DOAC) can replace warfarin. Despite a recent increase in evidence on the effectiveness and the importance of anticoagulant therapy in preventing thromboembolic events associated with NVAF, clinical prevention strategies remain complex. Given the complexities associated with clinical use of anticoagulants for patients with NVAF, this review aims to offer guidance on patient anticoagulant use based on current available evidence.

Keywords: anticoagulation; atrial fibrillation; clinical trial; direct-acting oral anticoagulant; non-valvular heart disease.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Mechanism of anticoagulant action.
See this image and copyright information in PMC

References

    1. Kirchhof P. The future of atrial fibrillation management: integrated care and stratified therapy. Lancet. (2017) 390:1873–87. 10.1016/S0140-6736(17)31072-3 - DOI - PubMed
    1. Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, et al. Heart disease and stroke statistics-2019 update: a report from the american heart association. Circulation. (2019) 139:e56–8. 10.1161/CIR.0000000000000659 - DOI - PubMed
    1. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors In Atrial Fibrillation (ATRIA) study. JAMA. (2001) 285:2370–5. 10.1001/jama.285.18.2370 - DOI - PubMed
    1. Björck S, Palaszewski B, Friberg L, Bergfeldt L. Atrial fibrillation, stroke risk, and warfarin therapy revisited. Stroke. (2013) 44:3103–8. 10.1161/STROKEAHA.113.002329 - DOI - PubMed
    1. You JJ, Singer DE, Howard PA, Lane DA, Eckman MH, Fang MC, et al. Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. (2012) 141:e531S−75S. 10.1378/chest.141.4.1129b - DOI - PMC - PubMed

LinkOut - more resources